

## Relative Environmental and Social Disadvantage in Patients with Idiopathic Pulmonary

### Fibrosis: Supplementary Material

Na'ama Avitzur MD<sup>1</sup>, Elizabeth M. Noth PhD MPH<sup>2</sup>, Mubasiru Lamidi<sup>3</sup>, Steven D. Nathan MD<sup>4</sup>,  
Harold R. Collard MD<sup>5</sup>, Alison M. DeDent MD<sup>5</sup>, Neeta Thakur MD MPH<sup>5</sup>, Kerri A. Johansson MD  
MPH<sup>1,6</sup>

<sup>1</sup>Department of Medicine, University of Calgary, Calgary, AB, Canada

<sup>2</sup>Division of Environmental Health Sciences, School of Public Health, University of California  
Berkeley, Berkeley, CA, USA

<sup>3</sup>Department of Biostatistics, University of Calgary, Calgary, AB, Canada

<sup>4</sup>Inova Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, VA, USA

<sup>5</sup>Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of  
California, San Francisco, San Francisco, CA, USA

<sup>6</sup>Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada

**Supplemental Figure: Marginal means of forced vital capacity (FVC) % and CalEnviroScreen****3.0 (CES) interaction coefficient**